Cell Therapeutics this week announced the management team for its recently-formed subsidiary Aequus BioPharma. Carl March has been chosen as president and CEO. Stewart Chipman will serve as executive vice president and CSO. David Cosman will join the company's board of directors.
Additional board members will include Jack Singer, Fred Telling, and James Bianco, who will serve as non-executive chairman.
March was previously senior vice president of information technology and biochemical sciences at Immunex. Chipman, currently the vice president of research at CTI, was previously Immunex’ director of biomolecular screening. Cosman, currently vice president of molecular biology at Immunex, was previously distinguished fellow and research director at Amgen.
CTI also announced this week that it will co-develop AQB-101 with Aequus BioPharma. AQB-101 is being developed as a follow-on biologic to help fight infection in some patients taking chemotherapy. AQB-101 is a genetic polymer-modified version of G-CSF.